69 related articles for article (PubMed ID: 29750040)
1. A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.
Bauer TM; Patel MR; Forero-Torres A; George TJ; Assad A; Du Y; Hurwitz H
Onco Targets Ther; 2018; 11():2399-2407. PubMed ID: 29750040
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus
Beatty GL; Shahda S; Beck T; Uppal N; Cohen SJ; Donehower R; Gabayan AE; Assad A; Switzky J; Zhen H; Von Hoff DD
Oncologist; 2019 Jan; 24(1):14-e10. PubMed ID: 30115734
[TBL] [Abstract][Full Text] [Related]
3. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.
Hidalgo M; Garcia-Carbonero R; Lim KH; Messersmith WA; Garrido-Laguna I; Borazanci E; Lowy AM; Medina Rodriguez L; Laheru D; Salvador-Barbero B; Malumbres M; Shields DJ; Grossman JE; Huang X; Tammaro M; Martini JF; Yu Y; Kern K; Macarulla T
Cancer Res Commun; 2022 Nov; 2(11):1326-1333. PubMed ID: 36970055
[TBL] [Abstract][Full Text] [Related]
4. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer.
Rehman H; Chi J; Hakim N; Goyal SP; Olazagasti C; Jose J; Moriarty L; Saif MW
Therap Adv Gastroenterol; 2020; 13():1756284820974912. PubMed ID: 33281939
[TBL] [Abstract][Full Text] [Related]
5.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
6. Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma.
Domadia K; Goel V; Koyyala VPB; Patnaik N; Chaudhari K; Raina S; Doval DC; Talwar V
South Asian J Cancer; 2022 Jan; 11(1):31-35. PubMed ID: 35833047
[TBL] [Abstract][Full Text] [Related]
7. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
9. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
[TBL] [Abstract][Full Text] [Related]
11. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
Hoy SM
Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
13. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
Hurwitz H; Van Cutsem E; Bendell J; Hidalgo M; Li CP; Salvo MG; Macarulla T; Sahai V; Sama A; Greeno E; Yu KH; Verslype C; Dawkins F; Walker C; Clark J; O'Reilly EM
Invest New Drugs; 2018 Aug; 36(4):683-695. PubMed ID: 29508247
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
18. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
Zhang Y; Hochster H; Stein S; Lacy J
Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
